It inhibits the phospholipid in infected cells as it possesses peroxisome proliferator-activated receptor alpha (PPARα) agonist activity, thus affecting the pathways of lipid metabolism in the lung cells of COVID-19 patients [40,41]. This evidence concerns the gene PPARA and COVID-19.